Equillium Beheer

Beheer criteriumcontroles 3/4

De CEO Equillium is Bruce Steel, benoemd in Jan2006, heeft een ambtstermijn van 18.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.35M, bestaande uit 33.8% salaris en 66.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 10.48% van de aandelen van het bedrijf, ter waarde $ 2.89M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.7 jaar en 6.2 jaar.

Belangrijke informatie

Bruce Steel

Algemeen directeur

US$1.3m

Totale compensatie

Percentage CEO-salaris	33.8%
Dienstverband CEO	18.8yrs
Eigendom CEO	10.5%
Management gemiddelde ambtstermijn	6.7yrs
Gemiddelde ambtstermijn bestuur	6.2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Bruce Steel's beloning veranderd ten opzichte van Equillium's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$5m
Jun 30 2024	n/a	n/a	-US$8m
Mar 31 2024	n/a	n/a	-US$12m
Dec 31 2023	US$1m	US$455k	-US$13m
Sep 30 2023	n/a	n/a	-US$8m
Jun 30 2023	n/a	n/a	-US$18m
Mar 31 2023	n/a	n/a	-US$29m
Dec 31 2022	US$2m	US$455k	-US$62m
Sep 30 2022	n/a	n/a	-US$76m
Jun 30 2022	n/a	n/a	-US$72m
Mar 31 2022	n/a	n/a	-US$67m
Dec 31 2021	US$2m	US$440k	-US$39m
Sep 30 2021	n/a	n/a	-US$37m
Jun 30 2021	n/a	n/a	-US$34m
Mar 31 2021	n/a	n/a	-US$31m
Dec 31 2020	US$782k	US$198k	-US$30m
Sep 30 2020	n/a	n/a	-US$28m
Jun 30 2020	n/a	n/a	-US$28m
Mar 31 2020	n/a	n/a	-US$27m
Dec 31 2019	US$1m	US$396k	-US$26m
Sep 30 2019	n/a	n/a	-US$23m
Jun 30 2019	n/a	n/a	-US$22m
Mar 31 2019	n/a	n/a	-US$18m
Dec 31 2018	US$452k	US$219k	-US$13m

Compensatie versus markt: De totale vergoeding ($USD 1.35M ) Bruce } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 354.57K ).

Compensatie versus inkomsten: De vergoeding van Bruce is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Bruce Steel (58 yo)

18.8yrs

Tenure

US$1,348,215

Compensatie

Mr. Bruce D. Steel, CFA has been Chief Executive Officer of Equillium, Inc. since January 1, 2020. He has been a Managing Director at BioMed Ventures LP since September 2010. Mr. Steel serves as President...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Daniel Bradbury	Executive Chairman	7.7yrs	US$267.30k	5.29% $ 1.5m
Bruce Steel	Co-Founder	18.8yrs	US$1.35m	10.48% $ 2.9m
Christine Zedelmayer	Senior VP & COO	6.8yrs	US$785.51k	0.38% $ 105.5k
Stephen Connelly	Chief Scientific Officer & Director	6.8yrs	US$827.25k	2.8% $ 774.4k
Jason Keyes	Chief Financial Officer	6.7yrs	geen gegevens	0.34% $ 94.9k
Penny Tom	Senior VP of Finance & Principal Accounting Officer	no data	geen gegevens	0.018% $ 5.1k
Michael Moore	Vice President of Investor Relations & Corporate Communications	no data	geen gegevens	geen gegevens
Matthew Ritter	Senior Vice President of Corporate Development	4.5yrs	geen gegevens	geen gegevens
Joel Rothman	Chief Development Officer	4.9yrs	geen gegevens	0.16% $ 45.4k

6.7yrs

Gemiddelde duur

54.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0A4D is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Daniel Bradbury	Executive Chairman	7.7yrs	US$267.30k	5.29% $ 1.5m
Bruce Steel	Co-Founder	7.7yrs	US$1.35m	10.48% $ 2.9m
Stephen Connelly	Chief Scientific Officer & Director	7.7yrs	US$827.25k	2.8% $ 774.4k
Martha Demski	Independent Director	6.2yrs	US$98.77k	0.067% $ 18.6k
Bala Manian	Independent Director	7.5yrs	US$101.79k	0.067% $ 18.6k
Thomas Daniel	Member of Scientific & Clinical Advisory Board	5.5yrs	geen gegevens	geen gegevens
Mark Pruzanski	Independent Director	6.2yrs	US$83.77k	0.067% $ 18.6k
Vijay Kuchroo	Member of Scientific & Clinical Advisory Board	no data	geen gegevens	geen gegevens
Barbara Troupin	Independent Director	2.8yrs	US$65.25k	0% $ 0
Charles McDermott	Independent Director	6.2yrs	US$60.69k	0.067% $ 18.6k
Fred Ramsdell	Member of Scientific & Clinical Advisory Board	no data	geen gegevens	geen gegevens
Yu Xu	Independent Director	3.8yrs	US$74.86k	0% $ 0

6.2yrs

Gemiddelde duur

60.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0A4D wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.2 jaar).

Equillium Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

Insufficient new directors

Equillium, Inc. Promotes Maple Fung to the Position of Chief Medical Officer

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

Third quarter 2024 earnings released: EPS: US$0 (vs US$0.11 loss in 3Q 2023)

Second quarter 2024 earnings released: EPS: US$0.013 (vs US$0.097 loss in 2Q 2023)

New major risk - Financial position

Equillium, Inc. Announces Positive Interim Analysis from Phase 3 Equator Study of Itolizumab in Acute Graft-Versus-Host Disease

Equillium Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Equillium, Inc. Announces Topline Data from Its Phase 2, Single Dose, Proof-Of-Concept Study of Eq101

Equillium, Inc. Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

New minor risk - Profitability

Forecast to breakeven in 2024

First quarter 2024 earnings released: US$0.078 loss per share (vs US$0.11 loss in 1Q 2023)

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1B Equalise Study of Itolizumab in Lupus Nephritis

New minor risk - Profitability

Forecast to breakeven in 2024

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

Equillium, Inc. Presents Positive Data from Phase 1B EQUALISE Study At the 2023 Annual Meeting of the American College of Rheumatology

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

Insufficient new directors

Equillium Gets an Additional 180-Day Grace Period to Regain Compliance with the Minimum Bid Price Requirement

Equillium Gets an Additional 180-Day Grace Period to Regain Compliance with the Minimum Bid Price Requirement

Insufficient new directors

Equillium, Inc. Promotes Maple Fung to the Position of Chief Medical Officer

Equillium, Inc. (NasdaqGM:EQ) announces an Equity Buyback for $7.5 million worth of its shares.

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Biocon Limited in Collaboration with Equillium, Inc. Initiate Phase 2 Clinical Study of Itolizumab in Patients with Ulcerative Colitis

Insufficient new directors

Equillium, Inc. Announces Initiation of Phase 2 Study of Eq101 A First-In-Class Multi-Cytokine Inhibitor of Il-2, Il-9 and Il-15 Targeting Alopecia Areata

Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease

Equillium, Inc. Reports Interim Results from the Type B Portion of the EQUALIZE Study Evaluating Itolizumab

Insufficient new directors

Equillium, Inc. (NasdaqGM:EQ) entered into a definitive merger agreement to acquire Metacrine, Inc. (NasdaqCM:MTCR).

Insufficient new directors

Equillium, Inc., Annual General Meeting, May 24, 2022

Equillium, Inc. Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line Acute Graft-Versus-Host Disease

Equillium, Inc. Appoints Barbara Troupin to its Board of Directors and as Member of Nominating and Corporate Governance Committee

Equillium, Inc. (NasdaqGM:EQ) completed the acquisition of Bioniz Therapeutics, Inc. from Kevin Green for $330 million.

Equillium Announces Data from Phase 1B Equip Study in Patients with Uncontrolled Asthma

High number of new directors

Equillium Announces Update to EQUALISE Study of Itolizumab in Patients with Systemic Lupus Erythematosus and Lupus Nephritis

High number of new directors

Equillium, Inc. Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA

Equillium, Inc.(NasdaqGM:EQ) dropped from Russell Microcap Value Index

Equillium Inc Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease

Equillium Presents Data on Target Engagement and Modulation of Cd6 on T Cells with Itolizumab at the International Society for Advancement of Cytometry

Forecast to breakeven in 2025

Equillium Announces Oral Presentation Highlighting Positive Data from the EQUATE Study in Acute Graft-Versus-Host Disease at the EHA2021 Virtual Congress of the European Hematology Association

Equillium, Inc. Announces Positive Data Supporting the Role of Itolizumab as A Potential Treatment for Acute Graft-Versus-Host Disease

Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience

Equillium, Inc. Appoints Yu (Katherine) Xu, Ph.D., as A Class II Director

Equillium, Inc.(NasdaqGM:EQ) dropped from Russell 2000 Dynamic Index

Equillium, Inc. Appoints Dolca Thomas as Executive Vice President of Research & Development and Chief Medical Officer, Effective January 11, 2021

Equillium Announces Positive Interim Data of Itolizumab in the First-Line Treatment of Acute Graft-Versus-Host Disease

Equillium, Inc. to Present Data at the 2020 American College of Rheumatology Meeting Demonstrating CD6 Modulation Improves Kidney and Skin Pathology in Preclinical Models of Systemic Lupus Erythematosus

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd